Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer's Prevnar, Sanofi-Aventis' ActHIB Vaccines Temporarily Suspended In Japan; Safety Committee Unwilling To Lift Action After First Meeting

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Japan's Ministry of Health, Labor and Welfare temporarily suspended Pfizer Inc.'s Prevnar and Sanofi-Aventis SA's ActHIB following the death of four infants and now the companies find themselves in front of Japan's cautious safety council awaiting a decision that has the potential to have a large commercial impact, particularly on the blockbuster Prevnar, the latest iteration of which - Prevnar 13, a 13-valent vaccine for both children and adults - is currently in Phase III trials in Japan
Advertisement

Related Content

Japan Clears Merck's Gardasil To Ease HPV Vaccine Shortage; AstraZeneca, Astellas Also Gain Approvals
Japan Clears Merck's Gardasil To Ease HPV Vaccine Shortage; AstraZeneca, Astellas Also Gain Approvals
Japan Pushing For Vaccine Advisory Committee To Address Drug Lag - PhRMA Symposium
Japan Pushing For Vaccine Advisory Committee To Address Drug Lag - PhRMA Symposium
Pfizer Vaccines President Mark Swindell On Prevenar 13 in Developing Countries And Emerging Markets: An Interview With PharmAsia News
Pfizer Vaccines President Mark Swindell On Prevenar 13 in Developing Countries And Emerging Markets: An Interview With PharmAsia News
Advertisement
UsernamePublicRestriction

Register

SC077601

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel